Integrating Nutrition and Exercise to Mitigate Cardiometabolic Risk and Enhance Outcomes in Lung Cancer During the Era of Immunotherapy and Targeted Therapy
Giuseppina Gallucci, Luigi Tarantini(Santa Maria Nuova Hospital), Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia), Silvia Di Leo(Azienda Sanitaria Unità Locale di Reggio Emilia), Debora Pezzuolo(University of Bergamo), Stefania Fugazzaro(Azienda Sanitaria Unità Locale di Reggio Emilia), Stefania Costi(University of Modena and Reggio Emilia), Carmine Pinto(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Alessandro Navazio(Presidio Ospedaliero), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Francesca Zanelli(Ospedale Santa Maria)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial
|Journal of Clinical Oncology|2011|763
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
|Modern Pathology|2015|317